FDA clears Neurotronics' sleep analysis module — no new hardware required

Neurotronics, the Nihon Kohden subsidiary behind the Polysmith sleep diagnostic platform, announced on Nov. 3 that its Sleep Analysis Module (SAM) received FDA 510(k) clearance, according to the company's press release. The clearance itself, filed under 510(k) number K261521, is recorded in the FDA's public device database. SAM is Neurotronics' first FDA-cleared AI/ML-based sleep analysis algorithm, and it ships with no new hardware: the module reads an existing photoplethysmography (PPG) signal captured by the NomadAir home sleep apnea testing device and derives a total sleep time estimate that clinicians can use alongside standard respiratory event data.

That's the detail worth pausing on. SAM isn't a new sensor, a new device class, or a new piece of equipment a clinic has to buy and stock — it's a software layer bolted onto data a device was already collecting. For a team evaluating whether to build a new hardware SKU or extend value from data its devices already generate, that's exactly the kind of decision a SaaS development partner is built to help make: ship the algorithm as a subscribed or licensed software module, keep the hardware unchanged, and get a faster, cheaper path through FDA review than a new device would require.

Why software-only clearances move faster than hardware ones

A 510(k) for a software module analyzing an existing signal has a narrower comparison problem than a hardware submission: the predicate device argument rests on algorithm performance against a reference standard, not on biocompatibility, electrical safety, or a new manufacturing line. That narrower scope is why software-only SaMD clearances — SAM included — have become a recognizable, repeatable pathway for device makers who already have a sensor in the field and want to extract more clinical value from the same data stream.

The product question this raises for device and clinic software teams

Most clinical hardware collects more signal than it currently reports on. The practical question SAM's clearance raises for a device maker or health system is whether that unused signal — vitals, imaging, waveform data already captured — justifies a software module of its own, and whether that module should be built, bought, or licensed. Scoping, validating, and shipping that kind of algorithm as a maintained software product, separate from the device release cycle, is a different engineering discipline than embedded firmware work, and it's where a dedicated software partner earns its keep.